Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency Immediately in Effect Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 8, 2019
May 6, 2020
d88af3f7-de54-4f46-bcc5-9dd57bf5f149
Related Documents
Temporary Policies for Compounding Certain Parenteral Drug Products: Guidance for Industry
Guidance DocumentOctober 11, 2024Center for Drug Evaluation and Research
Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act
Guidance DocumentNovember 18, 2022Center for Drug Evaluation and Research
Compounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Guidance DocumentFebruary 9, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.